Stock APGE APOGEE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Apogee Therapeutics, Inc.

Equities

APGE

US03770N1019

Market Closed - Nasdaq
Other stock markets
 04:00:03 2024-05-31 pm EDT 		5-day change 1st Jan Change
45.64 USD -1.55% Intraday chart for Apogee Therapeutics, Inc. -4.98% +63.35%
May. 28 Apogee Therapeutics, Inc. Appoints Lisa Bollinger to Its Board of Directors CI
May. 15 Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD
AQ
Apogee Therapeutics, Inc. Appoints Lisa Bollinger to Its Board of Directors
CI
Apogee Therapeutics to Participate in Upcoming June Investor Conferences
AQ
Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
AQ
Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
CI
Apogee Therapeutics' Q1 Net Loss Widens
MT
Apogee Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results
AQ
BofA Securities Starts Coverage on Apogee Therapeutics With Buy Rating, $80 Price Target
MT
Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference
AQ
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases
AQ
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody for the Treatment of Chronic Obstructive Pulmonary Disease and Other Inflammatory Diseases
CI
Apogee Therapeutics, Inc.(NasdaqGM:APGE) added to S&P Biotechnology Select Industry Index
CI
Apogee Closes $483 million Upsized Stock Offering
MT
Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million
AQ
Apogee Therapeutics Prices Upsized $420 Million Share Offering
MT
Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering
AQ
Sector Update: Health Care Stocks Advance Wednesday Afternoon
MT
Apogee Therapeutics Shares Rise After Jefferies Raises Price Target
MT
Jefferies Adjusts Price Target on Apogee Therapeutics to $75 From $37, Maintains Buy Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. APGE Stock
  4. News Apogee Therapeutics, Inc.